Showing results (31-40 of 87) with videos related to
Sort By:
Pageof 9
Clinical Prostate Cancer|July 29, 2004
Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veteransSara J Knight, Amy K Siston, Joan S Chmiel, et al.Clinical Prostate Cancer|July 29, 2004
Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: a potential early indicator for technology assessment?Pearl H Seo, Anthony V D'Amico, Jack A Clark, et al.Clinical Prostate Cancer|July 29, 2004
Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancerMiyako Abe, Judith B Manola, William K Oh, et al.Clinical Prostate Cancer|March 26, 2004
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancerAvi S Retter, William D Figg, William L DahutClinical Prostate Cancer|March 26, 2004
Population screening for prostate cancer and emerging concepts for young menJudd W MoulClinical Prostate Cancer|October 14, 2004
Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancerWilliam R Berry, James W Hathorn, Shaker R Dakhil, et al.Clinical Prostate Cancer|October 14, 2004
Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige micePamela A Davol, Janelle A Smith, Nicola Kouttab, et al.Clinical Prostate Cancer|May 11, 2005
Combined androgen blockade: the case for bicalutamideLaurence Klotz, Paul SchellhammerClinical Prostate Cancer|October 4, 2005
Second-line chemotherapy for prostate cancer: patient characteristics and survivalKathleen W Beekman, Mark T Fleming, Howard I Scher, et al.Clinical Prostate Cancer|October 4, 2005
Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancerRobert E Hawkins, Luc Daigneault, Richard Cowan, et al.Pageof 9